Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E3112 Single Ascending Dose Study in Healthy Japanese Males
NCT03014895Phase 1Completed
- Sponsor
- EA Pharma Co., Ltd.
- Start
- Jan 2017
- Primary completion
- Jun 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of olamepermin alfa in acute liver failure (ALF) (10 cohorts), sponsored by EA Pharma Co., Ltd. Primary endpoints: Peak concentration of E3112, Time to peak concentration of E3112 and 4 more. Started Jan 2017; status: completed.
02
Drugs
olamepermin alfa
03
Conditions
acute liver failure (ALF)
Beyond the preview
Go deeper on NCT03014895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03014895.